Webcast Alert: Aastrom Biosciences Announces Its Fourth Quarter Investor Conference Call
07 September 2006 - 5:46AM
Business Wire
Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following
Webcast: What: Aastrom Biosciences, Inc. Fourth Quarter Fiscal Year
End 2006 Investor Conference Call When: Wednesday, September 13,
2006 @ 11:00 am (EDT) Where:
http://www.vcall.com/IC/CEPage.asp?ID=107349 How: -- For live
Internet access, simply log on to the web at the address above. --
For phone access, interested parties should call toll-free (877)
407-9205 before the start of the call to register and identify
themselves as registrants of the "Aastrom Conference Call". Any
registered caller on the toll-free line may ask for call operator
for directions to be placed in the queue for the Question &
Answer session. If calling from outside the U.S., please use the
international phone number (201) 689-8054. -- To download the
podcast, simply log on to the web at the address above. Contact:
Kris Maly, Investor Relations Department, (734) 930-5777 or
mail@aastrom.com If you are unable to participate during the live
call, the webcast will be available for replay at
http://www.investorcalendar.com/ for 60 days. Through September 23,
2006, the audio replay of the call will be available by dialing
toll-free (877) 660-6853, or from outside the U.S. (201) 612-7415.
When prompted on the phone, the Account # is: 286, and the
Conference ID# is: 209872. Aastrom Biosciences, Inc. (Nasdaq: ASTM)
is developing autologous cell products for the repair or
regeneration of multiple human tissues, based on its proprietary
Tissue Repair Cell (TRC) technology. Aastrom's TRC-based products
are a unique cell mixture containing stromal, stem and progenitor
cell populations, produced outside the body from a small amount of
bone marrow taken from the patient. TRC-based products have been
used in over 225 patients, and are currently in clinical trials for
bone regeneration (long bone fractures and spine fusion) and
vascular regeneration (critical limb ischemia) applications. The
Company has reported positive interim clinical trial results for
TRCs suggesting both the clinical safety and the ability of TRCs to
induce tissue regeneration in long bone fractures and jaw bone
reconstruction. Recently, the Company's proprietary TRCs received
an Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) for use in the treatment of osteonecrosis of
the femoral head. In addition, Aastrom is developing plans for a
TRC-based therapy for cardiac regeneration. For more information,
visit Aastrom's website at www.aastrom.com.
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024